Skip to main content
. 2016 Jul 11;7(34):55276–55289. doi: 10.18632/oncotarget.10527

Table 3. Clinical Data of CD171 Positive GIST Cases.

Age Sex Primary Site CD171 Expression Genetic Tumor Size Mitosis Risk Follow-up Data
Positivity (%) Intensity Profile (cm) (/50HPF) Group (month) Outcome
41 F Stomach 100 Moderate SDH-deficient 7.0 19 6a 180 AWM
20 F Stomach 100 Weak SDH-deficient ND 7 - ND
19 M Stomach 100 Weak SDH-deficient 4.5 12 5 132 ANR
70 F Stomach 100 Weak KIT-Mutant Del 560 3.0 1 2 163 DOC
65 F Stomach 100 Weak KIT-Mutant V559D 5.0 0 2 ND
55 M Stomach 100 Weak KIT-Mutant Del 557-558 4.5 6 5 239 DOC
26 M Stomach 100 Weak KIT-Mutant Delins 563-576I 5.0 3 2 60 ANR
50 M Stomach 100 Weak KIT/PDGFRA Wild Type 5.0 6 5 32 ANR
70 M Stomach 100 Weak ND 7.5 0 3a 152 ANR
66 M Stomach 100 Strong ND 7.0 >100 6a 5 DOD
62 F Stomach 90 Weak PDGFRA-Mutant Delins 842-846E 5.0 11 5 28 DOC
67 M Stomach 80 Weak KIT/PDGFRA Wild Type 4.5 0 2 116 ANR
32 M Stomach 80 Weak ND 12.0 3 3b 158 DOD
53 M Stomach 40 Moderate ND 2.3 2 2 307 ANR
42 M Stomach 10 Weak KIT-Mutant Delins 567-576 V 6.0 1 3a 201 ANR
67 M Duodenum 100 Weak ND 3.0 >100 - 22 DOD
81 F Cecum 20 Weak ND ND 10 - ND
32 M Colon 10 Weak KIT/PDGFRA Wild Type 6.0 2 - ND
62 M Colon 60 Strong ND 7.5 >100 - ND
58 M Rectum 80 Moderate ND 0.8 44 - 203 DUC

GIST: gastrointestinal stromal tumor, ANR: alive with no recurrence, AWM: alive with metastasis, DOC: died of other cause, DOD: died of disease, DUC: died of unknown cause, ND: no data.